Osteomed Uses

sponsored
How do you administer this medicine?

What is Osteomed?

Osteomed is in the group of medicines called bisphosphonates (bis FOS fo nayts). It alters the cycle of bone formation and breakdown in the body. Osteomed slows bone loss while increasing bone mass, which may prevent bone fractures.

Osteomed is used in men and women to treat or prevent osteoporosis that is caused by menopause or by taking steroids. Osteomed is also used to increase bone mass in men who have osteoporosis, and to treat Paget's disease of bone in men and women.

Osteomed may also be used for purposes not listed in this medication guide.

Osteomed indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Treatment of Osteoporosis in Postmenopausal Women

Osteomed sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, Osteomed sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures).

Prevention of Osteoporosis in Postmenopausal Women

Osteomed sodium tablets are indicated for the prevention of postmenopausal osteoporosis.

Treatment to Increase Bone Mass in Men with Osteoporosis

Osteomed sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis.

Treatment of Glucocorticoid-Induced Osteoporosis

Osteomed sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.

Treatment of Paget's Disease of Bone

Osteomed sodium tablets are indicated for the treatment of Paget’s disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.

Important Limitations of Use

The optimal duration of use has not been determined. The safety and effectiveness of Osteomed sodium tablets for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

How should I use Osteomed?

Use Osteomed as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Osteomed comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Osteomed refilled.
  • Swallow Osteomed whole. Do not break, crush, chew, or suck on the tablet before swallowing.
  • Take Osteomed by mouth on an empty stomach in the morning at least 30 minutes before your first food, drink, or other medicine of the day. Do NOT take Osteomed at bedtime or before you get out of bed in the morning.
  • Take Osteomed with a full glass of plain water (8 oz/240 mL). Do not take Osteomed with mineral water, coffee, tea, or juice. Do not lie down for 30 minutes after taking Osteomed and until you eat your first food of the day.
  • Be sure you understand how to take Osteomed. Contact your doctor or pharmacist if you have any questions.
  • Continue to use Osteomed even if you feel well. Do not miss any doses.
  • If you miss a dose of Osteomed, do not take it later in the day. Skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses within the same day.

Ask your health care provider any questions you may have about how to use Osteomed.

Uses of Osteomed in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Prevention and treatment of post-menopausal osteoporosis in women.

Osteomed may be used in some cancers and diseases to slow down the activity of osteoclasts, the cells that break down bone. Increased activity of these cells increases the levels of calcium in the blood. Paget’s disease of the bone.

Osteomed description

Osteomed is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Paget’s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, Osteomed has a high affinity for bone mineral and is taken up during osteoclast resorption. Osteomed inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Osteomed is used for the treatment of osteoporosis and Paget’s disease.

Osteomed dosage

sponsored

Treatment Of Osteoporosis In Postmenopausal Women

The recommended dosage is one 70 mg effervescent tablet once weekly.

Treatment To Increase Bone Mass In Men With Osteoporosis

The recommended dosage is one 70 mg effervescent tablet once weekly.

Important Administration Instructions

Instruct patients to do the following to assure adequate drug absorption and to decrease the risk of esophageal adverse reactions: Waiting less than 30 minutes, or taking Osteomed with food, beverages (other than plain water) or other medications will lessen the effect of Osteomed by decreasing its absorption into the body.

  • Take Osteomed upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day.
  • Dissolve the effervescent tablet in 4 ounces room temperature plain water only (not mineral water or flavored water).
  • Wait at least 5 minutes after the effervescence stops and then stir the solution for approximately 10 seconds and ingest.
  • Avoid lying down for at least 30 minutes after taking Osteomed and until after their first food of the day.
  • Do not take Osteomed at bedtime or before arising for the day.
  • Failure to follow these instructions may increase the risk of esophageal adverse reactions.

Recommendations For Calcium And Vitamin D Supplementation

Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home-bound, or chronically ill) may need vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered.

Administration Instructions For Missed Doses

If the once-weekly dose is missed, instruct patients to take one dose on the morning after they remember. They should not take 2 doses on the same day but should return to taking one dose once a week, as originally scheduled on their chosen day.

How supplied

Dosage Forms And Strengths

Osteomed effervescent tablets are round, flat-faced, white to off-white tablets, 25 mm in diameter, with beveled edges, with “M” debossed on one side, containing 91.37 mg of Osteomed sodium, which is equivalent to 70 mg of free Osteomed.

Storage And Handling

Osteomed effervescent tablets are round, flat faced, white to off-white tablets with beveled edges and “M” debossed on one side. Osteomed effervescent tablets, 70 mg are provided in blisters made of aluminum foil composite, as follows:

NDC 0178-0101-02 carton containing 4 units of use blisters

NDC 0178-0101-03 carton containing 12 units of use blisters

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F), Protect from moisture. Store tablets in original blister package until use.

Manufactured for: Mission Pharmacal Company San Antonio, TX 78230 1355. Issued: February 2015

Osteomed interactions

See also:
What other drugs will affect Osteomed?

sponsored

Calcium Supplements/Antacids

Co-administration of Osteomed and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of Osteomed. Therefore, instruct patients to wait at least one-half hour after taking Osteomed before taking any other oral medications.

Aspirin

In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of Osteomed sodium greater than 10 mg and aspirin-containing products.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Osteomed may be administered to patients taking NSAIDs. In a 3-year, controlled, clinical study (n=2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking Osteomed sodium 5 or 10 mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with Osteomed.

Levothyroxine

The bioavailability of Osteomed was slightly decreased when Osteomed and levothyroxine were co-administered to healthy subjects.

Osteomed side effects

See also:
What are the possible side effects of Osteomed?

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Treatment of Osteoporosis in Postmenopausal Women

Daily Dosing

The safety of Osteomed sodium in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44 to 84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027) and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to Osteomed sodium. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 international units Vitamin D per day.

Among patients treated with Osteomed 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the Osteomed sodium group. The incidence of serious adverse event was 30.7% in the placebo group and 30.9% in the Osteomed sodium group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the Osteomed sodium group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either Osteomed sodium or placebo are presented in Table 1.

Table 1: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients
United States/

Multinational Studies

Fracture Intervention Trial
Osteomed Sodium*

%

(n=196)

Placebo

%

(n=397)

Osteomed Sodium†

%

(n=3236)

Placebo

%

(n=3223)

*10 mg/day for three years

† 5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years

Gastrointestinal

abdominal pain

6.6

4.8

1.5

1.5

nausea

3.6

4

1.1

1.5

dyspepsia

3.6

3.5

1.1

1.2

constipation

3.1

1.8

0

0.2

diarrhea

3.1

1.8

0.6

0.3

flatulence

2.6

0.5

0.2

0.3

acid regurgitation

2

4.3

1.1

0.9

esophageal ulcer

1.5

0

0.1

0.1

vomiting

1

1.5

0.2

0.3

dysphagia

1

0

0.1

0.1

abdominal distention

1

0.8

0

0

gastritis

0.5

1.3

0.6

0.7

Musculoskeletal

musculoskeletal (bone, muscle or joint) pain

4.1

2.5

0.4

0.3

muscle cramp

0

1

0.2

0.1

Nervous System/Psychiatric

headache

2.6

1.5

0.2

0.2

dizziness

0

1

0

0.1

Special Senses

taste perversion

0.5

1

0.1

0

Rash and erythema have occurred.

Gastrointestinal Adverse Reactions: One patient treated with Osteomed (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin, developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and Osteomed sodium were discontinued and the patient recovered. In the Study 1 and Study 2 populations, 49 to 54% had a history of gastrointestinal disorders at baseline and 54 to 89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies.

Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking Osteomed sodium versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to less than 8 mg/dL (2 mM) and serum phosphate to less than or equal to 2 mg/dL (0.65 mM) were similar in both treatment groups.

Weekly Dosing

The safety of Osteomed 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing Osteomed 70 mg once weekly and Osteomed 10 mg daily. The overall safety and tolerability profiles of once weekly Osteomed 70 mg and Osteomed 10 mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients in either treatment group are presented in Table 2.

Table 2: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients
Once Weekly

Osteomed

70 mg

%

(n=519)

Osteomed

10 mg/day

%

(n=370)

Gastrointestinal

abdominal pain

3.7

3

dyspepsia

2.7

2.2

acid regurgitation

1.9

2.4

nausea

1.9

2.4

abdominal distention

1

1.4

constipation

0.8

1.6

flatulence

0.4

1.6

gastritis

0.2

1.1

gastric ulcer

0

1.1

Musculoskeletal

musculoskeletal (bone, muscle, joint) pain

2.9

3.2

muscle cramp

0.2

1.1

Prevention of Osteoporosis in Postmenopausal Women

Daily Dosing

The safety of Osteomed 5 mg/day in postmenopausal women 40 to 60 years of age has been evaluated in three double-blind, placebo-controlled studies involving over 1,400 patients randomized to receive Osteomed for either two or three years. In these studies the overall safety profiles of Osteomed 5 mg/day and placebo were similar. Discontinuation of therapy due to any clinical adverse event occurred in 7.5% of 642 patients treated with Osteomed 5 mg/day and 5.7% of 648 patients treated with placebo.

Weekly Dosing

The safety of Osteomed 35 mg once weekly compared to Osteomed 5 mg daily was evaluated in a one-year, double-blind, multicenter study of 723 patients. The overall safety and tolerability profiles of once weekly Osteomed 35 mg and Osteomed 5 mg daily were similar.

The adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either once weekly Osteomed 35 mg, Osteomed 5 mg/day or placebo are presented in Table 3.

Table 3: Osteoporosis Prevention Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients
Two/Three-Year Studies One-Year Study
Osteomed

5 mg/day

%

(n=642)

Placebo

%

(n=648)

Osteomed

5 mg/day

%

(n=361)

Once Weekly

Osteomed

35 mg

%

(n=362)

Gastrointestinal

dyspepsia

1.9

1.4

2.2

1.7

abdominal pain

1.7

3.4

4.2

2.2

acid regurgitation

1.4

2.5

4.2

4.7

nausea

1.4

1.4

2.5

1.4

diarrhea

1.1

1.7

1.1

0.6

constipation

0.9

0.5

1.7

0.3

abdominal distention

0.2

0.3

1.4

1.1

Musculoskeletal

musculoskeletal (bone, muscle or joint) pain

0.8

0.9

1.9

2.2

Concomitant Use with Estrogen/Hormone Replacement Therapy

In two studies (of one and two years’ duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with Osteomed 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments.

Osteoporosis in Men

In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of Osteomed 10 mg/day and a one-year study of once weekly Osteomed 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for Osteomed 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly Osteomed 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either Osteomed sodium or placebo are presented in Table 4.

Table 4: Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 2% of Patients
Two-year Study One-year Study
Osteomed

10 mg/day

%

(n=146)

Placebo

%

(n=95)

Once Weekly Osteomed

70 mg

%

(n=109)

Placebo

%

(n=58)

Gastrointestinal

acid regurgitation

4.1

3.2

0

0

flatulence

4.1

1.1

0

0

gastroesophageal reflux disease

0.7

3.2

2.8

0

dyspepsia

3.4

0

2.8

1.7

diarrhea

1.4

1.1

2.8

0

abdominal pain

2.1

1.1

0.9

3.4

nausea

2.1

0

0

0

Glucocorticoid-Induced Osteoporosis

In two, one-year, placebo-controlled, double-blind, multicenter studies in patients receiving glucocorticoid treatment, the overall safety and tolerability profiles of Osteomed 5 and 10 mg/day were generally similar to that of placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either Osteomed 5 or 10 mg/day or placebo are presented in Table 5.

Table 5: One-Year Studies in Glucocorticoid-Treated Patients Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients
Osteomed

10 mg/day

%

(n=157)

Osteomed

5 mg/day

%

(n=161)

Placebo

%

(n=159)

Gastrointestinal

abdominal pain

3.2

1.9

0

acid regurgitation

2.5

1.9

1.3

constipation

1.3

0.6

0

melena

1.3

0

0

nausea

0.6

1.2

0.6

diarrhea

0

0

1.3

Nervous System/Psychiatric

headache

0.6

0

1.3

The overall safety and tolerability profile in the glucocorticoid-induced osteoporosis population that continued therapy for the second year of the studies (Osteomed sodium: n=147) was consistent with that observed in the first year.

Paget's Disease of Bone

In clinical studies (osteoporosis and Paget's disease), adverse events reported in 175 patients taking Osteomed 40 mg/day for 3 to 12 months were similar to those in postmenopausal women treated with Osteomed 10 mg/day. However, there was an apparent increased incidence of upper gastrointestinal adverse reactions in patients taking Osteomed 40 mg/day (17.7% Osteomed vs. 10.2% placebo). One case of esophagitis and two cases of gastritis resulted in discontinuation of treatment.

Additionally, musculoskeletal (bone, muscle or joint) pain, which has been described in patients with Paget's disease treated with other bisphosphonates, was considered by the investigators as possibly, probably, or definitely drug related in approximately 6% of patients treated with Osteomed 40 mg/day versus approximately 1% of patients treated with placebo, but rarely resulted in discontinuation of therapy. Discontinuation of therapy due to any clinical adverse events occurred in 6.4% of patients with Paget's disease treated with Osteomed 40 mg/day and 2.4% of patients treated with placebo.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Osteomed sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with Osteomed sodium, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema.

Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications, have also been reported.

Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported.

Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe, and incapacitating; joint swelling; low-energy femoral shaft and subtrochanteric fractures.

Nervous System: dizziness and vertigo.

Pulmonary: acute asthma exacerbations.

Skin: rash (occasionally with photosensitivity), pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Special Senses: uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal (focal osteonecrosis).

Osteomed contraindications

See also:
What is the most important information I should know about Osteomed?

Osteomed is contraindicated in patients with the following conditions:

  • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
  • Inability to stand or sit upright for at least 30 minutes

Do not administer Osteomed to patients at increased risk of aspiration

  • Hypocalcemia
  • Hypersensitivity to any component of this product. Hypersensitivity reactions including urticaria and angioedema have been reported.

Active ingredient matches for Osteomed:

Alendronic Acid in Lebanon.

Colecalciferol in Singapore.


Unit description / dosage (Manufacturer)Price, USD
Osteomed tab 20 mcg 30's (Wallace Pharm)

List of Osteomed substitutes (brand and generic names):

Osteomax tab 70 mg 8's (Solvang)
Tablet, Film-Coated; Oral; Alendronic Acid / Alendronate Sodium 70 mg (Silesia)
Ostex inj 3 mg/3 mL 1's (Nang Kuang Pharma)
Ostogee 70 mg Tablet (Swiss Pharma Pvt. Ltd.)$ 0.30
Ostomir 70 mg x 1 Blister x 4 Tablet
Tablet; Oral; Alendronic Acid / Alendronate Sodium Trihydrate 70 mg (Rider)
Liquid; Oral; Vitamin D3 / Cholecalciferol 400 units / ml
Pharmadronate 1 Blister x 4 Tablet
Pharmadronate 70 mg x 1 Blister x 4 Tablet
Tablet; Oral; Alendronic Acid / Alendronate Sodium 70 mg
PHL-alendronate tablet 70 mg (Pharmel Inc (Canada))
Tablet; Oral; Alendronic Acid / Alendronate Sodium 70 mg
Tablet; Oral; Alendronic Acid / Alendronate Sodium 70 mg

References

  1. DailyMed. "ALENDRONATE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "ALENDRONIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "ALENDRONIC ACID". http://www.drugbank.ca/drugs/DB00630 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Osteomed are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Osteomed. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


1 consumer reported price estimates

Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?
The below mentioned numbers have been reported by ndrugs.com website users about whether the Osteomed drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users%
Expensive1
100.0%


1 consumer reported time for results

To what extent do I have to use Osteomed before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Osteomed. To get the time effectiveness of using Osteomed drug by other patients, please click here.
Users%
1 day1
100.0%


4 consumers reported age

Users%
> 602
50.0%
< 11
25.0%
16-291
25.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 17 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved